Isotretinoin-Induced Hematuria in Acne Patients: Frequency, Risk Factors, and Management Recommendations from a Single-Center Study

Igor Kapetanovic; Jelena  Nojner; Ivan Soldatovic; Dubravka Zivanovic; Natasa  Maksimovic; Milos Nikolic; Snezana  Minic

doi:10.5826/dpc.1601a5768

Isotretinoin-Induced Hematuria in Acne Patients: Frequency, Risk Factors, and Management Recommendations from a Single-Center Study

Authors

Igor Kapetanovic Clinic of Dermatology and Venereology, University Clinical Center of Serbia https://orcid.org/0000-0003-4776-2312
Jelena Nojner Resident - Clinic of Dermatology and Venereology, University Clinical Center of Serbia https://orcid.org/0009-0008-4276-6166
Ivan Soldatovic Institute of Medical Statistics and Informatics, Faculty of Medicine, University of Belgrade https://orcid.org/0000-0003-4893-1683
Dubravka Zivanovic Clinic of Dermatology and Venereology, University Clinical Center of Serbia https://orcid.org/0000-0002-9011-3396
Natasa Maksimovic Institute of Epidemiology, Faculty of Medicine, University of Belgrade https://orcid.org/0000-0002-4397-2446
Milos Nikolic Clinic of Dermatology and Venereology, University Clinical Center of Serbia https://orcid.org/0000-0002-3926-5394
Snezana Minic Clinic of Dermatology and Venereology, University Clinical Center of Serbia and University of Belgrade School of Medicine https://orcid.org/0000-0003-2185-9749

Keywords:

hematuria, isotretinoin, Acne, Adverse drug reaction, Renal safety

Abstract

Introduction: Isotretinoin-induced hematuria is very rare; it has been reported in one study and individual case reports but never proven statistically.

Objectives: To determine whether hematuria is statistically more significant in isotretinoin-treated acne patients than in non-isotretinoin-treated patients.

Methods: Cohort study of acne patients treated at the University Clinic of Dermatology between 01 September 2022 and 31 March 2024.

Results: Eight hundred and sixty-four acne patients were treated and reviewed; 69.3% (599/864) were treated with modalities other than isotretinoin, while 30.7% (265/864) were treated with isotretinoin. Of the isotretinoin patients, only 26% (69/265) had urinalysis done at least once during therapy. In the isotretinoin group, 13% (9/69) had at least one episode of hematuria during treatment, as did 2.9% (2/70) in the control group. Hematuria is significantly more frequent in the isotretinoin group compared to control (P=0.026), with a 5.1 (95% confidence interval (CI): 1.06–24.5) higher risk. Of the isotretinoin-induced hematuria patients, 66.6% were male. The mean duration of isotretinoin use for hematuria was 2.78 months. Comorbidities and minimal and maximal isotretinoin dosage were not correlated with hematuria.

Conclusion: Hematuria is significantly more frequent in patients on isotretinoin and is a side-effect of isotretinoin. In the majority of cases, isotretinoin should be continued. Patients should be stratified according to risk factors per guidelines for microhematuria and referred to urologists. Urinalysis should be a part of routine monitoring in patients on isotretinoin especially at the 2- and 4-month intervals.

References

Dreno B, Poli F. Epidemiology of acne. Dermatology. 2003;206(1):7–10. DOI: 10.1159/000067817. PMID: 12566799.

Kutlu Ö, Karadağ AS, Wollina U. Adult acne versus adolescent acne: a narrative review with a focus on epidemiology to treatment. An Bras Dermatol. 2023;98(1):75–83. DOI: 10.1016/j.abd.2022.01.006. PMID: 36253244.

Thielitz A, Krautheim A, Gollnick H. Update in retinoid therapy of acne. Dermatol Ther. 2006;19(5):272–279. DOI: 10.1111/j.1529-8019.2006.00084.x. PMID: 17014482.

Santer M, Burden-Teh E, Ravenscroft J. Managing acne vulgaris: an update. Drug Ther Bul.l 2023;62(1):6–10. DOI: 10.1136/dtb.2023.000051. PMID: 38154809

Nelson AM, Zhao W, Gilliland KL, Zaenglein AL, Liu W, Thiboutot DM. Isotretinoin temporally regulates distinct sets of genes in patient skin. J Invest Dermatol. 2009;129(4):1038–1042. DOI: 10.1038/jid.2008.338. PMID: 18987667.

Ahmad HM. Analysis of clinical efficacy, side effects, and laboratory changes among patients with acne vulgaris receiving single versus twice daily dose of oral isotretinoin. Dermatol Ther. 2015;28(3):151–157. DOI: 10.1111/dth.12213. PMID: 25754162.

Forouzani-Haghighi B, Karimzadeh I. Isotretinoin and the Kidney: Opportunities and Threats. Clin Cosmet Investig Dermatol. 2020;13:485–494. DOI: 10.2147/CCID.S259048. PMID: 32801824

Yesilkaya B, Alli N, Artuz RF, Ulu E, Kartal D, Cinar SL. The frequency of hematuria in acne vulgaris patients during isotretinoin treatment. Cutan Ocul Toxicol. 2017;36(1):74–76. DOI: 10.3109/15569527.2016.1155595. PMID: 26938860.

Grossfeld GD, Litwin MS, Wolf JS et al. Evaluation of asymptomatic microscopic hematuria in adults: the American Urological Association best practice policy--part I: definition, detection, prevalence, and etiology. Urology. 2001;57(4):599–603. DOI: 10.1016/s0090-4295(01)00919-0. PMID: 11306356.

Barocas DA, Boorjian SA, Alvarez RD et al. Microhematuria: AUA/SUFU Guideline. J Urol. 2020;204(4):778-786. DOI: 10.1097/JU.0000000000001297. PMID: 32698717.

Pavese P, Kuentz F, Belleville C, Rougé PE, Elsener M. Renal impairment induced by isotretinoin. Nephrol Dial Transplant. 1997;12(6):1299. DOI: 10.1093/ndt/12.6.1299a. PMID: 9198075.

Sarifakioglu E, Yilmaz AE, Erpolat S. Terminal hematuria associated with oral isotretinoin treatment in a patient with acne vulgaris. Pediatr Dermatol. 2012;29(5):668–669. DOI: 10.1111/j.1525-1470.2011.01552.x. PMID: 22067016.

Erdik A, Cimen HI, Atik YT, Gul D, Pinar M. New J Urol. 2023;18(2):183-185. DOI : 10.33719/yud.2023;18-2-1210144.

Kapetanovic I, Zivanovic D, Mijuskovic M, Minic S. The unknown silent drug reaction in acne patients: rare case of isotretinoin-induced haematuria. Fam Pract. 2024;41(4):615-617. DOI: 10.1093/fampra/cmad043. PMID: 37602648.

McLane J. Analysis of common side effects of isotretinoin. J Am Acad Dermatol. 2001;45(5):S188-194. DOI: 10.1067/mjd.2001.113719. PMID: 11606952.

Khadra MH, Pickard RS, Charlton M, Powell PH, Neal DE. A prospective analysis of 1,930 patients with hematuria to evaluate current diagnostic practice. J Urol. 2000;163(2):524–527. DOI: 10.1016/S0022-5347(05)67916-5. PMID: 10647670.

Grossfeld GD, Carroll PR. Evaluation of asymptomatic microscopic hematuria. Urol Clin North Am. 1998;25(4):661–676. DOI: 10.1016/s0094-0143(05)70055-0. PMID: 10026773.

Sokolosky MC. Hematuria. Emerg Med Clin North Am. 2001;19(3):621–632. DOI: 10.1016/s0733-8627(05)70206-6. PMID: 11554278.

Quigley R. Evaluation of hematuria and proteinuria: how should a pediatrician proceed? Curr Opin Pediatr. 2008;20(2):140–144. DOI: 10.1097/MOP.0b013e3282f55f6c. PMID: 18332708.

Fallah H, Rademaker M. Isotretinoin for acne vulgaris - an update on adverse effects and laboratory monitoring. J Dermatolog Treat. 2022;33(5):2414–2424. DOI: 10.1080/09546634.2021.1967269. PMID: 34379039.

Öktem A, Hayran Y, Arı E, Yalçın B. Minimize the regular laboratory monitoring during the systemic isotretinoin treatment: data of 704 patients with acne vulgaris. J Dermatolog Treat. 2019;30(8):813–817. DOI: 10.1080/09546634.2019.1591578. PMID: 30836808.

Zane LT, Leyden WA, Marqueling AL, Manos MM. A population-based analysis of laboratory abnormalities during isotretinoin therapy for acne vulgaris. Arch Dermatol. 2006;142(8):1016–1022. DOI: 10.1001/archderm.142.8.1016. PMID: 16924051.

Landau M, Mesterman R, Ophir J et al. Clinical significance of markedly elevated serum creatine kinase levels in patients with acne on isotretinoin. Acta Dermato-Venereologica. 2001;81(5):350–352. DOI: 10.1080/000155501317140070. PMID: 11800143.

Woldu SL, Ng CK, Loo RK et al. Evaluation of the New American Urological Association Guidelines Risk Classification for Hematuria. J Urol. 2021;205(5):1387–1393. DOI: 10.1097/JU.0000000000001550. PMID: 33356483.

Loo RK, Lieberman SF, Slezak JM et al. Stratifying risk of urinary tract malignant tumors in patients with asymptomatic microscopic hematuria. Mayo Clin Proc. 2013;88(2):129–138. DOI: 10.1016/j.mayocp.2012.10.004. PMID: 23312369.

Ghandour R, Freifeld Y, Singla N, Lotan Y. Evaluation of Hematuria in a Large Public Health Care System. Bladder Cancer. 2019;5(2):119–129. DOI: 10.3233/BLC-190221. PMID: 31930164.